Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 2
1973 11
1974 11
1975 31
1976 33
1977 31
1978 24
1979 18
1980 18
1981 57
1982 34
1983 51
1984 48
1985 59
1986 84
1987 72
1988 96
1989 106
1990 115
1991 118
1992 125
1993 116
1994 129
1995 108
1996 120
1997 110
1998 117
1999 87
2000 88
2001 97
2002 85
2003 93
2004 90
2005 73
2006 87
2007 78
2008 93
2009 80
2010 82
2011 82
2012 70
2013 57
2014 73
2015 85
2016 70
2017 76
2018 44
2019 68
2020 66
2021 76
2022 59
2023 57
2024 70
2025 61
2026 48

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,713 results

Results by year

Filters applied: . Clear all
Page 1
CNS pharmacology of NKCC1 inhibitors.
Löscher W, Kaila K. Löscher W, et al. Neuropharmacology. 2022 Mar 1;205:108910. doi: 10.1016/j.neuropharm.2021.108910. Epub 2021 Dec 6. Neuropharmacology. 2022. PMID: 34883135 Free article. Review.
Bumetanide is known to have anticonvulsant and neuroprotective effects under some pathophysiological conditions. ...The main outcomes are that (1), non-acidic loop diuretics such as azosemide and torasemide may have advantages as NKCC1 inhibitors vs. bumetanide; (2) …
Bumetanide is known to have anticonvulsant and neuroprotective effects under some pathophysiological conditions. ...The main outcomes …
Bumetanide Treatment in 15 Children With Autism: A Randomised Waitlist-Control Study.
Fernell E, Landberg S, Miniscalco C, Fagerudd R, Johnels JÅ, Johnson M, Hadjikhani N, Gillberg C. Fernell E, et al. Acta Paediatr. 2025 Nov;114(11):2985-2992. doi: 10.1111/apa.70204. Epub 2025 Jun 26. Acta Paediatr. 2025. PMID: 40568982 Free PMC article. Clinical Trial.
AIM: Bumetanide, a diuretic, influences neuronal chloride homeostasis and potentially restores GABAergic inhibition and neuronal signalling balance. ...RESULTS: Two children had to be excluded in the first treatment period with bumetanide due to emerging behavioural …
AIM: Bumetanide, a diuretic, influences neuronal chloride homeostasis and potentially restores GABAergic inhibition and neuronal sign …
Clarifications regarding bumetanide for neonatal seizures.
Staley KJ. Staley KJ. Epilepsia. 2022 Jul;63(7):1863-1867. doi: 10.1111/epi.17278. Epub 2022 May 26. Epilepsia. 2022. PMID: 35524444 Free PMC article. Clinical Trial.
A recent Phase II randomized, controlled trial of bumetanide as an adjunctive treatment for neonatal seizures showed a robust efficacy signal and no evidence of toxicity. Concerns regarding bumetanide as an adjunctive anticonvulsant are addressed here. An adequately …
A recent Phase II randomized, controlled trial of bumetanide as an adjunctive treatment for neonatal seizures showed a robust efficac …
Bumetanide Nasal Spray: First Approval.
Blair HA. Blair HA. Clin Drug Investig. 2026 Feb;46(2):237-240. doi: 10.1007/s40261-025-01503-1. Epub 2025 Nov 12. Clin Drug Investig. 2026. PMID: 41222849 Review.
Bumetanide nasal spray (ENBUMYST( )) is a loop diuretic developed by Corstasis Therapeutics for the treatment of oedema. ...This article summarizes the milestones in the development of bumetanide nasal spray leading to this first approval for the treatment of oedema …
Bumetanide nasal spray (ENBUMYST( )) is a loop diuretic developed by Corstasis Therapeutics for the treatment of oedema. ...This arti …
Pharmacological tools to target NKCC1 in brain disorders.
Savardi A, Borgogno M, De Vivo M, Cancedda L. Savardi A, et al. Trends Pharmacol Sci. 2021 Dec;42(12):1009-1034. doi: 10.1016/j.tips.2021.09.005. Epub 2021 Oct 4. Trends Pharmacol Sci. 2021. PMID: 34620512 Free article. Review.
However, bumetanide has poor brain penetration and causes unwanted diuresis by inhibiting NKCC2 in the kidney. ...We also discuss the advantages and limitations of bumetanide repurposing and the benefits and risks of new NKCC1 inhibitors as therapeutic agents for br …
However, bumetanide has poor brain penetration and causes unwanted diuresis by inhibiting NKCC2 in the kidney. ...We also discuss the …
Efficacy of bumetanide in animal models of ischemic stroke: a systematic review and meta-analysis.
Sun X, Hou J, Xu H, Qu H. Sun X, et al. Aging (Albany NY). 2024 Jun 7;16(11):9959-9971. doi: 10.18632/aging.205910. Epub 2024 Jun 7. Aging (Albany NY). 2024. PMID: 38850525 Free PMC article.
Subgroup analyses demonstrated that bumetanide treatment reduced infarct volume in transient but not permanent cerebral ischemia models. ...Eight studies assessed the effect of bumetanide on behavioral function and the results showed that bumetanide treatment …
Subgroup analyses demonstrated that bumetanide treatment reduced infarct volume in transient but not permanent cerebral ischemia mode …
Clinical pharmacology of loop diuretics.
Brater DC. Brater DC. Drugs. 1991;41 Suppl 3:14-22. doi: 10.2165/00003495-199100413-00004. Drugs. 1991. PMID: 1712712 Review.
Whether such differences are clinically important requires further study. Bumetanide and torasemide are metabolised by cytochrome P450 pathways, whereas furosemide is glucuronidated. ...Thus, torasemide has a longer duration of action. The rank order of potency is bumet …
Whether such differences are clinically important requires further study. Bumetanide and torasemide are metabolised by cytochrome P45 …
Furosemide, bumetanide, and ethacrynic acid.
Hinchcliff KW, Mitten LA. Hinchcliff KW, et al. Vet Clin North Am Equine Pract. 1993 Dec;9(3):511-22. doi: 10.1016/s0749-0739(17)30383-8. Vet Clin North Am Equine Pract. 1993. PMID: 8299013 Review.
Furosemide and, less commonly, bumetanide and ethacrynic acid are potent diuretics administered to horses for a variety of reasons, including prophylaxis of exercise-induced pulmonary hemorrhage. ...
Furosemide and, less commonly, bumetanide and ethacrynic acid are potent diuretics administered to horses for a variety of reasons, i …
The Efficacy and Safety of Bumetanide in Children with Autism Spectrum Disorder: An Updated Meta-analysis.
Hendi NI, Almosilhy NA, Mohammed OH, Abdelrehim AM, Eisa A, Saddoun HAA, Belakhdar A. Hendi NI, et al. Eur Child Adolesc Psychiatry. 2026 Feb;35(2):413-425. doi: 10.1007/s00787-025-02890-8. Epub 2025 Oct 30. Eur Child Adolesc Psychiatry. 2026. PMID: 41165800 Free PMC article. Review.
This meta-analysis aims to evaluate the efficacy and safety of bumetanide on ASD symptom management. We included randomized controlled trials comparing bumetanide with placebo or conventional treatment. ...Although statistically significant improvements were observe …
This meta-analysis aims to evaluate the efficacy and safety of bumetanide on ASD symptom management. We included randomized controlle …
Bumetanide as a potential treatment for neurodegenerative and neurodevelopmental disorders: A systematic review.
McNamara O, Delany T, Kwakowsky A. McNamara O, et al. Biomed Pharmacother. 2026 Jul;200:119533. doi: 10.1016/j.biopha.2026.119533. Epub 2026 May 20. Biomed Pharmacother. 2026. PMID: 42161225 Free article.
Across in vivo and ex vivo models, bumetanide frequently restored hyperpolarizing GABAergic activity and attenuated behavioral and cognitive abnormalities, although translational relevance is constrained by limited central nervous system penetration following systemic admi …
Across in vivo and ex vivo models, bumetanide frequently restored hyperpolarizing GABAergic activity and attenuated behavioral and co …
3,713 results